`
`
`
`
`
`
`
`
`
`
`
`Entered: July 10, 2017
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________
`
`PAR PHARMACEUTICAL, INC.
`Petitioner
`
`v.
`
`NOVARTIS AG
`Patent Owner
`_______________________
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`_______________________
`
`Before LORA M. GREEN, CHRISTOPHER L. CRUMBLEY, and
`ROBERT A. POLLOCK, Administrative Patent Judges.
`
`
`PETITIONER’S UPDATED MANDATORY NOTICES
`
`
`
`
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`
`Pursuant
`
`to 37 C.F.R. § 42.8, Petitioner Par Pharmaceutical, Inc.
`
`(“Petitioner”) hereby submits the following Updated Mandatory Notices.
`
`Real Parties-In-Interest (§ 42.8(b)(1)) (UNCHANGED)
`
`1.
`Par is a real-party-in-interest for this proceeding. Par identifies the following
`
`additional entities as real-parties-in-interest: Endo International PLC; Endo DAC;
`
`Endo Management Limited; Endo Luxembourg Holding Company S.a.r.l.; Endo
`
`Luxembourg Finance Company I S.a.r.l.; Endo Luxembourg Finance Company II
`
`S.a.r.l.; Paladin Labs Canadian Holding Inc.; Paladin Labs Inc.; Luxembourg Endo
`
`Specialty Pharmaceuticals Holding I S.a r l.; Luxembourg Endo Specialty
`
`Pharmaceuticals Holding II S.a r l.; and Par Pharmaceutical Companies, Inc.
`
`2.
`Related Matters (§ 42.8(b)(2)) (UNCHANGED)
`Novartis Pharm. Corp. et al. v. Par Pharm., Inc., 1:14-cv-1289-RGA (D.
`
`Del.). Novartis Pharm. Corp. et al. v. Par Pharm., Inc., 1:14-cv-1494-RGA (D.
`
`Del.). Novartis Pharm. Corp. et al. v. Par Pharm., Inc., 1:15-cv-78-RGA (D. Del.).
`
`Novartis Pharm. Corp. et al. v. Par Pharm., Inc., 1:15-cv-475-RGA (D. Del.).
`
`Novartis Pharm. Corp. et al. v. Par Pharm., Inc., 1:15-cv-1050-RGA (D. Del.).
`
`Roxane Labs., Inc. v. Novartis AG, IPR2016-1461 (filed July 19, 2016). Petitions
`
`for Inter Partes Review of U.S. Patent No. 5,665,772, Nos. IPR2016-00084, -
`
`01023, -01059, -01102, and -01103. According to USPTO records, U.S. Patent
`
`App. No. 14/608,644 claims priority to the ’224 patent.
`
`1
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`
`3.
`
`Lead and Back-Up Counsel (§ 42.8(b)(3)) (UPDATED)
`
`Lead Counsel
`Daniel G. Brown (Reg. No. 54,005)
`daniel.brown@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`T: 212.906.1200; F: 212.751.4864
`
`
`
`
`Back-Up Counsel
`Jonathan M. Strang (Reg. No. 61,724)
`jonathan.strang@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`555 Eleventh Street, NW, Ste. 1000
`Washington, DC 20004-1304
`T: 202.637.2200; F: 202.637.2201
`Back-Up Counsel
`Brenda L. Danek (Reg. No. 57,596)
`brenda.danek@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`330 North Wabash Avenue, Ste. 2800
`Chicago, IL 60611
`T: 312.876.7700; F: 312.993.9767
`
`4.
`
`Service Information (§ 42.8(b)(4)) (UPDATED)
`
`Lead Counsel
`Daniel G. Brown (Reg. No. 54,005)
`daniel.brown@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`T: 212.906.1200; F: 212.751.4864
`
`
`
`
`Back-Up Counsel
`Jonathan M. Strang (Reg. No. 61,724)
`jonathan.strang@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`555 Eleventh Street, NW, Ste. 1000
`Washington, DC 20004-1304
`T: 202.637.2200; F: 202.637.2201
`
`2
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`
`
`
`
`
`Dated: July 10, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Back-Up Counsel
`Brenda L. Danek (Reg. No. 57,596)
`brenda.danek@lw.com
`Postal & Hand-Delivery Address:
`Latham & Watkins LLP
`330 North Wabash Avenue, Ste. 2800
`Chicago, IL 60611
`T: 312.876.7700; F: 312.993.9767
`
`
`
`
`
`
`
`
`By: /Daniel G. Brown/
`
`
`
`
`
`
`
`
`
`
`Daniel G. Brown (Reg. No. 54,005)
`daniel.brown@lw.com
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`212.906.1200; 212.751.4864 (Fax)
`
`Counsel for Petitioner Par
`Pharmaceutical, Inc.
`
`
`
`3
`
`
`
`Case IPR2016-01479
`U.S. Patent No. 9,006,224
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 10th day of July,
`
`2017, a copy of Petitioner’s Updated Mandatory Notices was served by elec-
`
`tronic mail on Patent Owner’s lead and backup counsel at the following email ad-
`
`dresses:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Nicholas N. Kallas (Reg. No. 31,530)
`Raymond R. Mandra (Reg. No. 34,382)
`Charlotte Jacobsen (pro hac vice)
`Fitzpatrick, Cella, Harper & Scinto
`1290 Avenue of the Americas
`New York, NY 10104-3800
`ZortressAfinitorIPR@fchs.com
`
`
`
`By: /Daniel G. Brown/
`
`
`
`
`Daniel G. Brown (Reg. No. 54,005)
`daniel.brown@lw.com
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`212.906.1200; 212.751.4864 (Fax)
`
`Counsel for Petitioner Par
`Pharmaceutical, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`